Condition category
Circulatory System
Date applied
19/05/2010
Date assigned
19/05/2010
Last edited
11/08/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Davis Dutka

ORCID ID

Contact details

University of Cambridge
Addenbrookes Hospital
Hills Road
Cambridge
CB2 2QQ
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

6562

Study information

Scientific title

Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia

Acronym

GLP-1 and left ventricular function during ischaemia

Study hypothesis

The hypothesis is that infusion of glucagon-like peptide-1 will protect the heart from ischaemia and improve left ventricular (LV) function during dobutamine stress echocardiography in patients with coronary artery disease

Ethics approval

MREC approved, ref: 08/H0304/68

Study design

Single-centre non-randomised interventional treatment trial

Primary study design

Interventional

Secondary study design

Non randomised study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Condition

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Intervention

In the active DSE, patients will receive an infusion of GLP-1 intravenously at 1.2 pmol/kg/min starting 30 minutes prior to the DSE and continuing for 30 minutes into recovery. In the control scan there will be no infusion.

Intervention type

Drug

Phase

Not Applicable

Drug names

Glucagon-like peptide-1

Primary outcome measures

Global LV function at peak stress

Secondary outcome measures

1. Global LV function at 30 minutes recovery
2. Regional wall LV function at 30 minutes recovery
3. Regional wall LV function at peak stress

Overall trial start date

17/06/2009

Overall trial end date

30/07/2010

Reason abandoned

Eligibility

Participant inclusion criteria

Not provided at time of registration

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

Planned sample size: 30; UK sample size: 30

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

17/06/2009

Recruitment end date

30/07/2010

Locations

Countries of recruitment

United Kingdom

Trial participating centre

University of Cambridge
Cambridge
CB2 2QQ
United Kingdom

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

Sponsor details

Addenbrookes Hospital
Hills Road
Cambridge
CB2 2QQ
United Kingdom

Sponsor type

Government

Website

http://www.cuh.org.uk/

Funders

Funder type

Research council

Funder name

Medical Research Council (MRC) (UK)

Alternative name(s)

MRC

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21561896
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26253538

Publication citations

  1. Results

    Read PA, Khan FZ, Dutka DP, Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease., Heart, 2012, 98, 5, 408-413, doi: 10.1136/hrt.2010.219345.

  2. Results

    McCormick LM, Heck PM, Ring LS, Kydd AC, Clarke SJ, Hoole SP, Dutka DP, Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus, Cardiovasc Diabetol, 2015, 14, 102, doi: 10.1186/s12933-015-0259-3.

Additional files

Editorial Notes